Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Contract Revenue $ 1,096
Costs and Expenses:    
Research and development 3,970 4,978
General and administrative 2,712 2,744
Total costs and expenses 6,682 7,722
Loss from operations (5,586) (7,722)
Sale of New Jersey net operating loss & tax credits 1,734
Other income, net 73 10
Net loss $ (5,513) $ (5,978)
Net loss per share – basic and diluted $ (0.03) $ (0.03)
Weighted average common shares outstanding:    
Basic and diluted 217,264,526 216,644,783
Other comprehensive gain/(loss), net of tax    
Unrealized gain/(loss) on securities available-for-sale $ 229 $ (484)
Other comprehensive gain/(loss), net of tax 229 (484)
Comprehensive loss $ (5,284) $ (6,462)